Biomarker

Comparative proteomic analysis of ductal and lobular invasive breast carcinoma

N. C. S. Oliveira, Gomig, T. H. B., Milioli, H. H., Cordeiro, F., Costa, G. G., Urban, C. A., Lima, R. S., Cavalli, I. J., Ribeiro, E. M. S. F., Oliveira, N. C. S., Gomig, T. H. B., Milioli, H. H., Cordeiro, F., Costa, G. G., Urban, C. A., Lima, R. S., Cavalli, I. J., Ribeiro, E. M. S. F., Oliveira, N. C. S., Gomig, T. H. B., Milioli, H. H., Cordeiro, F., Costa, G. G., Urban, C. A., Lima, R. S., Cavalli, I. J., and Ribeiro, E. M. S. F., Comparative proteomic analysis of ductal and lobular invasive breast carcinoma, vol. 15, p. -, 2016.

Breast cancer is the second most common cancer worldwide and the first among women. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two major histological subtypes, and the clinical and molecular differences between them justify the search for new markers to distinguish them. As proteomic analysis allows for a powerful and analytical approach to identify potential biomarkers, we performed a comparative analysis of IDC and ILC samples by using two-dimensional electrophoresis and mass spectrometry.

Deep RNA sequencing elucidates microRNA-regulated molecular pathways in ischemic cardiomyopathy and nonischemic cardiomyopathy

X. Li, Liu, C. Y., Li, Y. S., Xu, J., Li, D. G., Han, D., Li, X., Liu, C. Y., Li, Y. S., Xu, J., Li, D. G., Han, D., Li, X., Liu, C. Y., Li, Y. S., Xu, J., Li, D. G., and Han, D., Deep RNA sequencing elucidates microRNA-regulated molecular pathways in ischemic cardiomyopathy and nonischemic cardiomyopathy, vol. 15, p. -, 2016.

Deregulation of cardiac miRNA gene-regulatory networks is a feature of different heart diseases, including ischemic (ICM) and nonischemic (NICM) cardiomyopathy. Here, based on the paired miRNA and mRNA expression profiles in ICM and NICM, we identified the differentially expressed miRNAs and mRNAs and the expression signatures distinguishing ICM/NICM from control samples. Furthermore, we constructed a functional miRNA network for each disease.

Subscribe to Biomarker